UniCAR-T-CD-123

N/A

Report date: 2026/01/23 20:01:08

Base Information

Drug NameUniCAR-T-CD-123
Drug Alias Name4-1BB costimulator+peptideexpressing anti-CD123 targeting molecule+anti-peptide CAR T-cell therapyTM-123 4-1BBLTM-123+UniCAR-TUniCAR-T-CD123AVC-101
ClassificationBiologics
Mechanisms of ActionT lymphocyte replacementsAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAvenCell Therapeutics IncAvenCell Europe GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvenCell Europe GmbH
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A